5-(3-溴苯基)-环己烷-1,3-二酮 | 144128-71-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-(3-溴苯基)-环己烷-1,3-二酮
• 英文名称: 5-(3'-bromophenyl)cyclohexane-1,3-dione
• 英文别名: 5-(3-Bromophenyl)cyclohexane-1,3-dione
• CAS: 144128-71-2
• 化学式: C₁₂H₁₁BrO₂
• 分子量: 267.122
• InChiKey: YZWQTKIZVUKNPW-UHFFFAOYSA-N

物化性质

• 沸点：
  399.4±42.0 °C(Predicted)
• 密度：
  1.485±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(3-溴苯基)-环己烷-1,3-二酮 在 三(2-甲氧基苯基)膦 、 palladium diacetate 、 N,N-二异丙基乙胺 作用下， 以 水 、 甲苯 为溶剂， 反应 35.0h， 生成 1-(3'-chlorophenyl)-5-(3'-bromophenyl)cyclohexane-1-en-3-one
  参考文献：
  名称：

  钯催化的烯基羧酸盐的交叉偶联。

  摘要：

  羧酸酯具有许多理想的功能，可作为亲电试剂用于催化交叉偶联：它们易于获得，在多步合成过程中稳定且在偶联反应中具有质量效率。链烯基羧酸盐是一类易于制备的非芳族亲电试剂，仍然难以通过交叉偶联官能化。我们证明，在没有碱或氧化剂的情况下，钯催化可有效地将缺电子的烯基羧酸盐与芳基硼酸偶联。此外，这些反应可以通过两种不同的C-O键激活机制进行。钯0 / II使用Pd时催化循环是可行的0预催化剂，具有限制营业额的C-O氧化加成；但是，对于Pd II预催化剂，提出了另一种途径，涉及烯烃的碳链反应和β-羧基的消除。这项工作为使多种基于氧的亲电试剂参与Pd催化的交叉偶联提供了一条清晰的途径。

  DOI：

  10.1002/anie.202006586
• 作为产物：
  描述：

  4-(3-Bromphenyl)-3-buten-2-on 在 sodium hydroxide 、 硫酸 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 12.5h， 生成 5-(3-溴苯基)-环己烷-1,3-二酮
  参考文献：
  名称：

  Antimalarial drugs. 64. Synthesis and antimalarial properties of 1-imino derivatives of 7-chloro-3-substituted-3,4-dihydro-1,9(2H,10H)-acridinediones and related structures

  摘要：

  To improve upon the activity and properties of the 3-aryl-7-chloro-3,4-dihydro-1,9(2H,10H)-acridinediones, a variety of 1-[(alkylamino)alkylene]imino derivatives (3) were prepared and shown to be highly active antimalarial agents in both rodents and primates. Among structural modifications prepared, including N-10-alkyl and C2-substituted analogs, removal of the C-9 oxygen, and introduction of an imino side chain at C-9, the imines of the N-10-H acridinediones were the most active compounds obtained. The [3-(NN-dimethylamino)propyl]imino derivative of 7-chloro-3-(2,4-dichlorophenyl)-3,4-dihydro-1,9(2H,10H)-acridinedione (9aa) proved to be highly active in advanced studies in primates.

  DOI：

  10.1021/jm00097a001

文献信息

• Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06350749B1

  公开（公告）日：2002-02-26

  The present invention is to provide a compound of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic heterocyclic ring, the ring B an optionally substituted 5- to 6-membered aromatic homocyclic ring or an optionally substituted 5- to 6-membered aromatic heterocyclic ring, R1 is a hydrogen atom, a hydroxy group or a lower alkyl group, and n is 0 or 1, or a salt thereof, which is effective for the prevention or treatment of ischemic cardiac disease, etc., and which is useful as an agent for preventing or treating ischemic cardiac disease, etc. such as myocardial infarction, arrhythmia, etc.

  本发明提供了一种化合物的公式：其中环A是可选地取代的5至6成员芳香杂环，环B是可选地取代的5至6成员的芳香同环或可选地取代的5至6成员的芳香杂环，R1是氢原子，羟基或低烷基，n是0或1，或其盐，该盐对于预防或治疗缺血性心脏病等有效，并可作为预防或治疗缺血性心脏病等的药物，例如心肌梗死、心律失常等。
• Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis
  申请人：Kirsch Donald R.

  公开号：US20120264765A1

  公开（公告）日：2012-10-18

  The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds.

  本发明涉及提供的环己烷-1,3-二酮（CHD化合物）的鉴定及其制备的药物组合物，用于治疗患有肌萎缩侧索硬化症（ALS）和其他神经退行性疾病的受试者。本发明还提供了制备所述CHD化合物的方法。
• AMINOGUANIDINE HYDRAZONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS THEREOF
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1057812A1

  公开（公告）日：2000-12-06

  The present invention is to provide a compound of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic heterocyclic ring, the ring B an optionally substituted 5- to 6-membered aromatic homocyclic ring or an optionally substituted 5- to 6-membered aromatic heterocyclic ring, R1 is a hydrogen atom, a hydroxy group or a lower alkyl group, and n is 0 or 1, or a salt thereof, which is effective for the prevention or treatment of ischemic cardiac disease, etc., and which is useful as preventing or treating agent for ischemic cardiac disease, etc. such as myocardial infarction, arrhythmia, etc.

  本发明旨在提供一种式化合物： 其中环A为任选取代的5-6元芳香杂环，环B为任选取代的5-6元芳香均环或任选取代的5-6元芳香杂环，R1为氢原子、羟基或低级烷基，n为0或1，或其盐，可有效预防或治疗缺血性心脏病等、可用作心肌梗塞、心律失常等缺血性心脏病的预防或治疗剂。
• PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLIC ENAMINONE DERIVATIVES
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1229019A1

  公开（公告）日：2002-08-07

  A process for the production of optically active cyclic enaminone derivatives characterized by aminating one of the carbonyl groups of a cyclic 1,3-diketone derivative having a symmetry plane to obtain an optically isomeric mixture of chiral cyclic enaminone derivatives and subjecting this mixture to optical resolution.

  一种生产光学活性环烯丙酮衍生物的工艺，其特征在于将具有对称平面的环 1，3-二酮衍生物的一个羰基胺化，得到手性环烯丙酮衍生物的光学异构体混合物，并对该混合物进行光学解析。
• Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells
  作者：Wei Zhang、Radhia Benmohamed、Anthony C. Arvanites、Richard I. Morimoto、Robert J. Ferrante、Donald R. Kirsch、Richard B. Silverman

  DOI：10.1016/j.bmc.2011.11.039

  日期：2012.1

  Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. Currently, there is only one FDA-approved treatment for ALS (riluzole), and that drug only extends life, on average, by 2-3 months. Mutations in Cu/Zn superoxide dismutase (SOD1) are found in familial forms of the disease and have played an important role in the study of ALS pathophysiology. On the basis of their activity in a PC12-G93A-YFP high-throughput screening assay, several bioactive compounds have been identified and classified as cyclohexane-1,3-dione (CHD) derivatives. A concise and efficient synthetic route has been developed to provide diverse CHD analogs. The structural modification of the CHD scaffold led to the discovery of a more potent analog (26) with an EC(50) of 700 nM having good pharmacokinetic properties, such as high solubility, low human and mouse metabolic potential, and relatively good plasma stability. It was also found to efficiently penetrate the blood-brain barrier. However, compound 26 did not exhibit any significant life span extension in the ALS mouse model. It was found that, although 26 was active in PC12 cells, it had poor activity in other cell types, including primary cortical neurons, indicating that it can penetrate into the brain, but is not active in neuronal cells, potentially due to poor selective cell penetration. Further structural modification of the CHD scaffold was aimed at improving global cell activity as well as maintaining potency. Two new analogs (71 and 73) were synthesized, which had significantly enhanced cortical neuronal cell permeability, as well as similar potency to that of 26 in the PC12-G93A assay. These CHD analogs are being investigated further as novel therapeutic candidates for ALS. (C) 2011 Elsevier Ltd. All rights reserved.